DaVita HealthCare Partners Inc. (NYSE:DVA) was upgraded by Raymond James Financial Inc. from a “market perform” rating to an “outperform” rating in a note issued to investors on Tuesday. The brokerage presently has a $75.00 target price on the stock. Raymond James Financial Inc.’s price objective suggests a potential upside of 15.40% from the company’s current price.

DVA has been the subject of a number of other research reports. JPMorgan Chase & Co. raised their price objective on DaVita HealthCare Partners from $74.00 to $75.00 and gave the company a “neutral” rating in a research note on Tuesday, August 9th. Zacks Investment Research cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research note on Wednesday, July 27th. Wells Fargo & Co. reissued a “buy” rating on shares of DaVita HealthCare Partners in a research note on Saturday, June 4th. Citigroup Inc. started coverage on DaVita HealthCare Partners in a report on Tuesday, September 6th. They issued a “neutral” rating and a $71.00 target price on the stock. Finally, TheStreet lowered DaVita HealthCare Partners from a “buy” rating to a “hold” rating in a report on Monday, August 8th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $76.36.

Shares of DaVita HealthCare Partners (NYSE:DVA) traded up 2.19% on Tuesday, reaching $64.99. The company’s stock had a trading volume of 1,873,187 shares. The stock has a market cap of $13.45 billion, a P/E ratio of 37.81 and a beta of 1.07. The firm’s 50 day moving average is $67.46 and its 200-day moving average is $73.22. DaVita HealthCare Partners has a 52-week low of $61.36 and a 52-week high of $78.94.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/davita-healthcare-partners-inc-dva-rating-increased-to-outperform-at-raymond-james-financial-inc.html

DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings data on Monday, August 8th. The company reported $1.01 EPS for the quarter, beating the Zacks’ consensus estimate of $0.98 by $0.03. DaVita HealthCare Partners had a return on equity of 16.48% and a net margin of 2.51%. The firm earned $3.72 billion during the quarter, compared to analysts’ expectations of $3.67 billion. During the same quarter last year, the firm posted $0.95 earnings per share. The company’s revenue for the quarter was up 8.2% compared to the same quarter last year. On average, equities research analysts forecast that DaVita HealthCare Partners will post $3.76 EPS for the current year.

In other news, insider Jeanine Marie Jiganti sold 4,620 shares of DaVita HealthCare Partners stock in a transaction on Friday, July 1st. The stock was sold at an average price of $77.45, for a total value of $357,819.00. Following the completion of the transaction, the insider now directly owns 7,590 shares in the company, valued at $587,845.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, COO Michael David Staffieri sold 20,262 shares of DaVita HealthCare Partners stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $73.09, for a total value of $1,480,949.58. Following the completion of the transaction, the chief operating officer now owns 52,279 shares of the company’s stock, valued at $3,821,072.11. The disclosure for this sale can be found here. 2.10% of the stock is owned by company insiders.

Several institutional investors have recently made changes to their positions in DVA. Geode Capital Management LLC boosted its position in shares of DaVita HealthCare Partners by 1.0% in the first quarter. Geode Capital Management LLC now owns 1,417,807 shares of the company’s stock valued at $103,840,000 after buying an additional 13,776 shares during the period. State Board of Administration of Florida Retirement System boosted its position in shares of DaVita HealthCare Partners by 19.7% in the second quarter. State Board of Administration of Florida Retirement System now owns 277,939 shares of the company’s stock valued at $21,490,000 after buying an additional 45,749 shares during the period. ING Groep NV bought a new position in shares of DaVita HealthCare Partners during the first quarter valued at $278,000. Arizona State Retirement System boosted its position in shares of DaVita HealthCare Partners by 0.6% in the first quarter. Arizona State Retirement System now owns 99,086 shares of the company’s stock valued at $7,271,000 after buying an additional 600 shares during the period. Finally, AMP Capital Investors Ltd boosted its position in shares of DaVita HealthCare Partners by 1.5% in the first quarter. AMP Capital Investors Ltd now owns 53,733 shares of the company’s stock valued at $3,924,000 after buying an additional 800 shares during the period. Institutional investors own 83.65% of the company’s stock.

About DaVita HealthCare Partners

DaVita HealthCare Partners Inc is a provider of kidney care services. The Company operates Kidney Care division and HealthCare Partners (HCP) division. Its segments include U.S. dialysis and related lab services, HCP and Other-Ancillary services and strategic initiatives. Its Kidney Care division is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD).

5 Day Chart for NYSE:DVA

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.